Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05579639 · ClinicalTrials.gov registry record · Phase 2
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
A Phase 2 study of Allogeneic Stem Cell Transplantation, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 419
- Enrollment target
- 3
- Study locations
NCT05579639: Recruiting Phase 2 study of Allogeneic Stem Cell Transplantation, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT05579639 is a Phase 2 study of Allogeneic Stem Cell Transplantation that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 419 participants, above the 58-participant average among 3 other Allogeneic Stem Cell Transplantation trials with a reported enrollment target (622% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05579639, a Phase 2 study of Allogeneic Stem Cell Transplantation, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 419 participants
- Enrollment target
- 3
- Study locations
Study Summary
Bloodstream infections (BSI) caused by bacteria translocating across injured oral mucosa are a significant cause of morbidity and mortality in patients undergoing stem cell transplantation (SCT). Unfortunately, there are currently no known strategies to prevent these BSI in this vulnerable population. The investigators will conduct a randomized, double-blind, placebo-controlled trial at three institutions to evaluate the effectiveness of twice daily intraoral xylitol-wipe application on reducing BSI in pediatric SCT patients.
Primary Outcome
Incidence of bloodstream infection (BSI) from oral flora organisms in in patients receiving xylitol compared to placebo
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Xylitol
Study Locations (3)
Colorado
- Children's Hospital Colorado - Aurora
Massachusetts
- Dana-Farber/Boston Children's - Boston
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 419 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
What NCT05579639 shows while recruiting
NCT05579639 is an interventional study that assigns participants to a tested intervention. The registered 419 participants enrollment target is mid-sized for trials with a published cap, above the 58-participant average among 3 other Allogeneic Stem Cell Transplantation trials with a reported enrollment target (622% higher).
The record links to 1 condition, with Allogeneic Stem Cell Transplantation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05579639 reports a single indexed study location in Colorado, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT05579639 about?
NCT05579639 is a clinical study titled "Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant". Bloodstream infections (BSI) caused by bacteria translocating across injured oral mucosa are a significant cause of morbidity and mortality in patients undergoing stem cell transplantation (SCT). Unfortunately, there are currently no known strategies to prevent these BSI in this vulnerable populatio...
What is the current status of trial NCT05579639?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 419 participants. The study started on 2023-04-04. Estimated completion is 2027-06-30.
What conditions does trial NCT05579639 study?
This clinical trial studies the following conditions: Allogeneic Stem Cell Transplantation.
What interventions are being tested in trial NCT05579639?
The interventions under investigation include: Placebo (OTHER), Xylitol (OTHER).
Who is sponsoring clinical trial NCT05579639?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05579639 being conducted?
This trial has 3 study locations across Colorado, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allogeneic Stem Cell Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT
RECRUITING · Phase 2
-
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
RECRUITING · Phase 2
-
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
ACTIVE NOT RECRUITING · Phase 2
-
Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
RECRUITING
-
CIBMTR Research Database
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI